NP 000888

Drug Profile

NP 000888

Alternative Names: NP-000888

Latest Information Update: 25 Feb 2017

Price : $50

At a glance

  • Originator Galderma
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psoriasis

Most Recent Events

  • 08 Feb 2017 Phase-II clinical trials in Psoriasis in Taiwan (Topical) (NCT02995473)
  • 14 Dec 2016 Preclinical trials in Psoriasis in Taiwan (Topical)
  • 01 Dec 2016 Galderma plans a phase II trial for Psoriasis in Taiwan (NCT02995473)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top